Search clinical trials for: Sintilimab , Carboplatin, Nab-paclitaxel

Total 2131 results

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Neoadjuvant Sintilimab Combined With Reduction of Cycles of Chemotherapy in Resectable Oral Cavity or Oropharyngeal Squamous Cell Carcinoma (OOC-002)

Oropharyngeal Squamous Cell Carcinoma | Oral Squamous Cell Carcinoma | Oral Cavity Squamous Cell Carcinoma

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Neoadjuvant Sintilimab in Combination With Carboplatin and Nab-paclitaxel in Untreated Salivary Gland Malignant Neoplasms

Salivary Gland Tumors | Salivary Gland Malignant Neoplasms

China
Sichuan University

Recruiting

Safety and Efficacy of Neoadjuvant Immunochemotherapy in Elderly Patients With Resectable Esophageal Cancer

Esophageal Cancer

China
Guangdong Provincial People's Hospital

Recruiting

Neoadjuvant Immunotherapy in EGFR-mutant Localized NSCLC (NEOTIDE)

Non-small Cell Lung Cancer | EGFR Activating Mutation

China
Shengjing Hospital

Recruiting

Treatment of Triple-negative Breast Cancer With Albumin-bound Paclitaxel as Neoadjuvant Therapy: a Prospective RCT

Breast Cancer

China
Jiuda Zhao

Recruiting

Efficacy and Safety of Sintilimab and Apatinib Combined Chemotherapy in Breast Cancer

Breast Cancer

China
Tianjin Medical University Cancer Institute and...

Not yet recruiting

Conversion Therapy of Sintilimab in Combination With Fruquintinib and Chemotherapy Versus Sintilimab and Chemotherpay in Stage IV Gastric Cancer

Gastric Cancer | Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

China
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer

Inflammatory Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative

United States
Shanghai General Hospital, Shanghai Jiao Tong University...

Unknown

A Trial of Paclitaxel (Albumin-binding) for Castration-resistant Prostate Cancer

Castration-resistant Prostate Cancer
Hebei Medical University Fourth Hospital
Beijing 302 Hospital; CSPC Ouyi Pharmaceutical Co., Ltd.

Unknown

Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced Triple-negative Breast Cancer

Triple Negative Breast Cancer | Nab-paclitaxel

China
Shengjing Hospital

Recruiting

Stereotactic Radiotherapy Combined With Adebrelimab and TCb (Nab-paclitaxel + Carboplatin) in Neoadjuvant Treatment of TNBC

Breast Cancer | Immunotherapy | Stereotactic Radiotherapy

China
Women's Hospital School Of Medicine Zhejiang University
Sun Yat-sen University; Qilu Hospital of Shandong University; Second Affiliated... and other collaborators

Recruiting

Nab-paclitaxel Versus Sb-taxanes As First-Line Treatment in Advanced Ovarian Cancer

Epithelial Ovarian Carcinoma Stage III | Epithelial Ovarian Carcinoma Stage IV | Fallopian Tube Carcinoma Stage III | Fallopian Tube Carcinoma Stage IV | Primary Peritoneal Carcinoma Stage III | Primary Peritoneal Carcinoma Stage IV

China
Zhejiang Cancer Hospital

Unknown

A Study of Sintilimab Plus Chemoradiation Before Surgery for Esophageal Cancer

Esophageal Squamous Cell Carcinoma

China
Cancer Institute and Hospital, Chinese Academy...
Beijing Friendship Hospital; Chinese PLA General Hospital; Beijing Hospital

Recruiting

Sintilimab and Nab-paclitaxel in Second-line Treatment of Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma

Advanced Gastric and Gastro-esophageal Junction Adenocarcinoma

China
RenJi Hospital

Recruiting

the Predictive Value of Immune Cell in Locally Advanced Cervical Cancer

Immunotherapy | Locally Advanced Cervical Carcinoma | Concurrent Chemoradiotherapy

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung Cancer

Non-Small Cell Lung Cancer

China
Shengyu Zhou

Unknown

Sintilimab in Combination With Nab-paclitaxel in Patients With HNSCC (Head and Neck Squamous Cell Carcinoma ) (HNSCC)

Head and Neck Squamous Cell Cancer

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Neoadjuvant Sintilimab in Combination With Carboplatin and Nab-paclitaxel in Resectable Oral Cavity or Oropharyngeal Squamous Cell Carcinoma (OOC-001)

Oropharyngeal Squamous Cell Carcinoma | Oral Squamous Cell Carcinoma

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Guangdong Provincial People's Hospital; Third Affiliated Hospital, Sun Yat-Sen...

Recruiting

Neoadjuvant Camrelizumab, Nab-paclitaxel and Carboplatin in Stage IB-IIIA NSCLC

Lung Cancer, Non-small Cell | Artificial Intelligence

China
Hebei Medical University Fourth Hospital
Beijing 302 Hospital; CSPC Ouyi Pharmaceutical Co., Ltd.

Unknown

Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer

Breast Cancer | Triple-negative Breast Cancer | Nab-paclitaxel

China
The First Affiliated Hospital with Nanjing Medical...

Recruiting

Sintilimab, Anlotinib Hydrochloride and Platinum-Containing Dual-Agent Chemotherapy in NSCLC

Metastatic NSCLC | Recurrent NSCLC | Advanced Non-Small Cell Squamous Lung Cancer

China
Wu Jun

Not yet recruiting

Efficacy and Safety of Sintilimab Combined With Nab-paclitaxel and Tegio (aTS) as First-line Treatment of Unresectable Locally Advanced, Recurrent or Metastatic Adenocarcinoma of Gastric and Gastroesophageal Junction，a Phase II Clinical Study

Adenocarcinoma | Gastric Cancer | GastroEsophageal Cancer

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Not yet recruiting

Neoadjuvant Toripalimab in Combination With Carboplatin and Nab-paclitaxel in Untreated Salivary Gland Malignant Neoplasms

Salivary Gland Tumors | Salivary Gland Malignant Neoplasms

China
Laekna Limited

Recruiting

Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1

Cervical Cancer | Esophageal Cancer | NSCLC | Solid Tumor | Endometrial Cancer | Gastric and Gastroesophageal Junction Adenocarcinoma

China
Shanghai Henlius Biotech

Active, not recruiting

A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy (Carboplatin-Nanoparticle Albumin Bound (Nab) Paclitaxel) in Patients With Stage IIIB/IIIC or IV NSCLC

Squamous Non Small Cell Lung Cancer

China, Turkey, United States, Georgia, Poland, Russian Federation, Ukraine
Sichuan Cancer Hospital and Research Institute
First Affiliated Hospital Xi'an Jiaotong University; General Hospital of Ningxia... and other collaborators

Unknown

Sintilimab Injection Combined With Concurrent CCRT in Locally Advanced Esophageal Squamous Cell Carcinoma

Locally Advanced Esophageal Squamous Cell Carcinoma

China
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Terminated

Ph I/II Nab-Paclitaxel & Carboplatin w/Concurrent Radiation Therapy for Unresectable Stg III NSCLC

Lung Cancer

United States
ImmunityBio, Inc.

Active, not recruiting

QUILT 2.023: A Study of N-803 in Combination With Current Standard of Care vs Standard of Care as First-Line Treatment for Patients With Stage 3 or 4 NSCLC.

Non Small Cell Lung Cancer

United States
Shanghai Chest Hospital

Not yet recruiting

Neoadjuvant Adebrelimab Plus Chemotherapy for Resectable ESCC: a Single Arm, Prospective Phase 2 Clinical Trial

Esophageal Squamous Cell Carcinoma

China
The First Affiliated Hospital of Zhengzhou University

Not yet recruiting

Candonilimab (AK104) Plus Preoperative Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma (ESCC)

Esophageal Squamous Cell Carcinoma

China
Wuhan University
CSPC Ouyi Pharmaceutical Co., Ltd.

Terminated

Concurrent Nab-P/Carboplatin and Thoracic Radiotherapy in Squamous Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung | Squamous Cell Carcinoma

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Neoadjuvant Toripalimab or Toripalimab in Combination With Carboplatin and Nab-paclitaxel in Untreated HNSCC (HNSCC-002)

Head and Neck Squamous Cell Carcinoma

China
Liaoning Tumor Hospital & Institute

Not yet recruiting

Adebrelimab Plus Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC Harboring Driver Gene Mutations

Non Small Cell Lung Cancer
Fudan University

Active, not recruiting

An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC. (FUTURE-SUPER)

TNBC - Triple-Negative Breast Cancer

China
Ruijin Hospital

Recruiting

Nab-PTX Plus S-1 and Sintilimab as Adjuvant Therapy in Patients With Stage IIIC Gastric Cancer

Stage IIIC Gastric Cancer

China
Hao Long

Recruiting

Predictive Biomarker for Efficacy and Safety of Combination of Chemotherapy and Tislelizumab in NSCLC

Chemotherapy | Safety | Biomarker | Tislelizumab

China
Shanghai Pulmonary Hospital, Shanghai, China

Recruiting

Neoadjuvant Durvalumab/Anlotinib /Chemotherapy Plus Curative Resection in Stage III Non-Small-Cell Lung Cancer : A Single-arm Phase II Study

Non Small Cell Lung Cancer

China
Jinghui Wang

Recruiting

A Prospective, Single-arm, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Tafolecimab and Sintilimab Combined With Chemotherapy in Patients With Advanced or Metastatic Driver Gene-negative Non-small Cell Lung Cancer After Failure of First-line Immunotherapy.

Lung Cancer

China
Wake Forest University Health Sciences
Celgene

Completed

LCI-LUN-ABR-001: Carbo With Nab-Paclitaxel in Patients With Advanced NSCL Cancer

Lung Cancer

United States
Guangdong Provincial People's Hospital

Recruiting

Neoadjuvant Almonertinib Followed by Chemo-immunotherapy in II-IIIB EGFR-mutant NSCLC (NEOVADE)

Non Small Cell Lung Cancer | EGFR Gene Mutation

China
Celgene

Completed

Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly (ABOUND 70+)

Adenocarcinoma | Carcinoma | Non-Small Cell Lung Cancer | Carcinoma, Large Cell | Squamous Cell Carcinoma | Lung Neoplasm

United States
Tang-Du Hospital

Recruiting

A Neoadjuvant Study of Sintilimab Plus Platinum Doublet Chemotherapy in IIIA(N2) Stage NSCLC

Non Small Cell Lung Cancer

China
Yale University

Terminated

Single Agent Versus Combination Chemotherapy to Treat High-risk Elderly With Non-small Cell Lung Cancer

Carcinoma, Non-small Cell Lung

United States
Zhejiang Cancer Hospital

Not yet recruiting

The Efficacy and Safety of Lenvatinib Combined With Sindilimab and Nab-paclitaxel in the First-line Treatment for Recurrent and Metastatic Triple Negative Breast Cancer: a Phase Ib/IIa Clinical Trial.

Breast Neoplasms

China
Fudan University

Recruiting

Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC.

Triple-Negative Breast Cancer

China
Shanghai Zhongshan Hospital
Fudan University

Not yet recruiting

Neoadjuvant/Adjuvant Sintilimab, Nab-paclitaxel, and Gemcitabine for Resectable/Borderline Resectable Pancreatic Cancer

Pancreatic Cancer Stage III | Pancreatic Cancer, Stage IB | Pancreatic Cancer, Stage IIA | Pancreatic Cancer, Stage IIB

China
Shanghai Chest Hospital

Not yet recruiting

Camrelizumab Combined With Neoadjuvant Concurrent Chemoradiotherapy for Resectable Locally Advanced ESCC（NICE-RT）

Esophageal Squamous Cell Carcinoma

China
iOMEDICO AG
Bristol-Myers Squibb

Completed

Nab-Paclitaxel in Combination With Carboplatin as First-line Therapy in Patients With NSCLC (NEPTUN)

Carcinoma, Non-Small-Cell Lung

Germany
Barwon Health
Australasian Gastro-Intestinal Trials Group; Deakin University; Specialised Therapeutics...

Unknown

A Feasibility Study Of NAB-Paclitaxel In Combination With Carboplatin As First Line Treatment Of Gastrointestinal Neuroendocrine Carcinomas (NABNEC)

Gastrointestinal Neuroendocrine Carcinomas

Australia
Guangdong Association of Clinical Trials
Bristol-Myers Squibb

Recruiting

A Two-arm (Phase 2) Exploratory Study of Nivolumab Monotherapy or in Combination With Nab-paclitaxel and Carboplatin in Early Stage NSCLC in China

Non Small Cell Lung Cancer

China

Search clinical trials for: Sintilimab , Carboplatin, Nab-paclitaxel

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Senegal

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations